Chugai launches Lunsumio in Japan for follicular lymphoma

20 March 2025

Chugai Pharmaceutical (TYO: 4519) has launched Lunsumio (mosunetuzumab) in Japan for patients with relapsed or refractory follicular lymphoma who have undergone at least two prior standard therapies. Approved by the Ministry of Health, Labor and Welfare in December 2024, Lunsumio is now listed on the National Health Insurance reimbursement price list.

Lunsumio is a bispecific antibody targeting CD20 on B cells and CD3 on T cells, designed to activate the immune system to eliminate cancerous B cells. Clinical trials have demonstrated high complete response rates and the potential for durable remission. The treatment is administered over a fixed duration, based on each patient's response, potentially reducing the treatment burden.

The approval was supported by a Japanese Phase I study and an overseas Phase I/II clinical trial conducted by Roche (ROG: SIX), both evaluating Lunsumio's efficacy and safety as a monotherapy in patients with relapsed or refractory follicular lymphoma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK